baber/WOPTO huggingface dataset:
Patent AT-E310020-T1 (AT)
Inventor: ZIMMERMANN ULRICH
IPC: A23L29/256
Filed: 1999-08-12
Granted: 2005-12-15
Abstract: The present invention relates to a method for obtaining a composition of ultra-pure alginate, wherein said method comprises the following steps: extracting a material consisting of algae or raw alginate using a complexing agent in a solution; allowing the cellular constituents and the particles contained in the solution to settle; filtering the solution; precipitating the alginate contained in the solution and recovering the precipitated alginate. An alginate composition in the form of a mixed polymer consisting of mannuronic and guluronic acids has a ratio between the mannuronic acid and the guluronic acid of about 1 to 90 % and an average molecular weight of 1000 kD or above.
Patent AT-E274488-T1 (AT)
Inventor: PANANDIKER KAMLESH P
IPC: C08G63/02
Filed: 1999-09-09
Granted: 2004-09-15
Abstract: A low temperature curing powder coating composition includes a combination of a branched oligoester polyol and a nonemissive uretdione polyisocyanate cross-linking agent. A powder coating composition comprises a branched hydroxyl terminated oligoester polyol having a hydroxyl value of 15-250, an acid number of 1-25 and a number average molecular weight of 1000-7500, which is the product of a hydroxyl terminated oligoester diol and a poly acid or anhydride having a carboxyl functionality of at least 3 and a uretdione crosslinking agent. The composition cures at less than 160[deg]C with a urethane catalyst and 160[deg]C without catalyst and the cured coating binder has a pencil hardness of at least HB, direct and reverse impact resistances of at least 80 in lb at a cured film thickness of 0.8-4 mils; the composition has a T gof at least 40[deg]C. Independent claims are also included for the following: (a) a process for preparing the composition above comprising blending the reactants above so that there is an equivalent ratio of isocyanate: hydroxyl groups of 0.5-1.8:1; (b) a branched hydroxyl-terminated oligoester polyol composition as above comprising the reaction product of a diol as above having a number average molecular weight of 400-1500 and at least a tri-carboxylic acid; and (c) a process for preparing the branched hydroxyl-terminated oligoester polyol above comprising blending the diol above with a polyacid. This hydroxy-terminated oligoester diol is the reaction product of a diol and a di-acid selected from an open chain aliphatic, cycloaliphatic, or aromatic dicarboxylic acid, anhydride or acid halide and has a number average molecular weight of 400-1500.
Patent AT-E267227-T1 (AT)
Inventor: EICHLER HANS-JUERGEN
IPC: C08L101/00
Filed: 1999-09-14
Granted: 2004-06-15
Abstract: Surface-modified filling material composition for thermoplastic, duroplastic or elastomeric materials, which is a halogen-free, flame-retardant filling material. The filling material is surface-treated with organotitanates and/or with organozirconates and with a siloxane derivative.
Patent AT-E274217-T1 (AT)
Inventor: DRUMMOND BRIAN L
IPC: G06T1/20
Filed: 1999-09-23
Granted: 2004-09-15
Abstract: One aspect of the present invention is directed to an apparatus for generating an image using an algorithm. The algorithm has a plurality of tasks for determining the level of energy emanating from a source located within a mass. The apparatus comprises memory configured to store information defining a trace. The trace defines energy levels recorded at a sensor. The amplitude of the trace at one or more given instants of time is the sum of energy received from two or more sources. A data processor is in electrical communication with the memory and the data processor is configured to simultaneously execute two or more tasks of the algorithm and determine the level of energy emanating from each source.
Patent AT-E344594-T1 (AT)
Inventor: NAKAMURA TSUYOSHI
IPC: H04N19/42
Filed: 1999-12-10
Granted: 2006-11-15
Abstract: A filter operation apparatus according to the present invention involves a vertical and horizontal half-pixel motion compensation and vertical and horizontal intra-loop filtering means 100 comprising a first pixel delay means 200, a second pixel delay means 201, a multiplication means 202, a left shift means 203, a first selection means 204, an addition means 205, a second selection means 206, a selection control signal generation means 207, a third pixel delay means 208, a right shift means 209, and a shift amount control means 210. The so-constructed operation apparatus can share an operation unit in a horizontal processing apparatus and a vertical processing apparatus in the processing of half-pixel motion compensation and intra-loop filtering for input pixel data, thereby reducing the scale of hardware. <IMAGE>
Patent DE-10196240-T1 (DE)
Inventor: KINOSE YUTAKA
IPC: H05K1/03
Filed: 2001-05-24
Abstract: The red phosphorus base flame retardant for an epoxy resin is provided, which has red phosphorus particles coated with a thermosetting resin containing an anhydrous zinc compound. The coated red phosphorus has properties that a slurry having the coated red phosphorus dispersed in 10% by weight into water at 20° C. has an electric conductivity of 30 mus/cm or below, the slurry having been left standing at 80° C. for 20 hours has an electric conductivity of 150 mus/cm or below, and when 80 ml of water is added to 8 g of the coated red phosphorus and heated at 80° C. for 20 hours, a concentration of PO4 ions eluted is 10 ppm or below.
Patent DE-104538-T1 (DE)
IPC: A45F3/04
Filed: 1983-09-13
Abstract: There is provided a back pack having an internal frame consisting of a T-shaped stay having its vertical member centrally positioned to overlie the user's spine. A load-transmitting, flexible, one-point connector extends between the pack bag, at the lower terminus of the frame, and the central rear segment of the hip belt. Stabilizer straps are provided to limit the movement of the pack bag. The one-point flexible connector permits of universal relative movement between the hip belt and the frame and associated pack bag, thereby providing a high level of capacity in the back pack to accommodate the movements of the user.
Patent DE-733729-T1 (DE)
Inventor: BRABANT MARC
IPC: D21F3/10
Filed: 1996-03-11
Abstract: The mechanism to transfer a fibre web (1) between a conveyor belt (2) and two calender rollers (3a, 3b) has a suction cylinder (4) with a fixed vacuum zone (A, B) which rotates in the direction of the conveyor belt (2) movement and against the rotation of the lower calender roller (3a). It lies on the web (1) path between the conveyor belt (2) and the two calender rollers (3a, 3b), at or near a tangent to the lower calender roller (3a). It gives an initial calender action, and the web (1) clings to the lower roller (3a) to be carried to the upper roller (3b). In addition, the suction cylinder (4) is at a level near the belt (2) for the web (1) to be held by suction against its surface (5a) as far as the pre-calender zone between the cylinder (4) and the lower roller (3a).
Patent ES-2304911-T1 (ES)
Title: Sales de magnesio de inhibidores de hmg-coa reductasa.
Inventor: KUMAR YATENDRA
IPC: C07D207/34
Filed: 2006-05-03
Abstract: Forma cristalina de una sal magnésica de atorvastatina.
Patent ES-2041228-T1 (ES)
IPC: C10M105/74
Filed: 1988-05-31
Abstract: A process for the production of aluminum cans to be used as beverage containers, in which the formed cans are cleaned with liquid acidic or alkaline cleaners to remove aluminum fines and other contaminants from at least the outside of said cans, the thus-cleaned cans are dried, and the dried cans are thereafter conveyed along a production line towards a station at which the thus-cleaned-and-dried cans are printed, lacquered and/or filled, in which in order to enhance the mobility of the cans along the production line one reduces the high coefficient of static friction of the dried exterior surface of the cans without preventing the adhesion of lacquer or printing ink thereto by applying to the exterior surface of the cans, before the last drying before the cans are printed, lacquered and/or filled, a water-soluble organic surface conditioner so as to form a film of the latter on the exterior surfaces of the dried cans.
Patent ES-2144987-T1 (ES)
Inventor: LAVEAN GIL
IPC: H04W56/00
Filed: 1998-02-26
Abstract: The present invention provides a method for reverse-link synchronization comprising: 
transmitting from a mobile terminal to a base station a signal in a reverse-link direction wherein a timing used for said signal is set according to a transmission received in a forward-link direction from the base station; 
at the base station: 
detecting a synchronization sequence in the transmitted signal; 
evaluating the timing of said transmitted signal; and  
sending timing adjustment information as synchronization commands, the synchronization commands indicating timing adjustments in one-eighth of a chip increments, to the mobile terminal based on said evaluation.
Patent CY-1108011-T1 (CY)
Inventor: KLEIN THOMAS
IPC: A61K45/06
Filed: 2007-05-07
Abstract: The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof.
Patent CY-1110691-T1 (CY)
Title: 2-αρυλ-προπιονικα οξεα και φαρμακευτικες συνθεσεις που τα περιεχουν
Inventor: ALLEGRETTI MARCELLO
IPC: C07C311/21
Filed: 2009-12-23
Abstract: Τα (R) και (S) 2-Αρυλ-προπιονικά οξέα, και οι φαρμακευτικές συνθέσεις που τα περιέχουν, είναι χρήσιμα στην αναστολή χημειοτακτικής ενεργοποίησης ουδετερόφιλων (ΡΜΝ λευκοκυττάρων) που διεγείρεται από την αλληλεπίδραση της Ιντερλευκίνης-8 (IL-8) με τους CXCR1 και CXCR2 υποδοχείς μεμβράνης. Τα οξέα χρησιμοποιούνται για την πρόληψη και θεραπεία παθολογιών που προέρχονται από την αναφερθείσα ενεργοποίηση. Συγκεκριμένα, τα (R) εναντιομερή των αναφερθέντων οξέων στερούνται δραστικότητας αναστολής κυκλο-οξυγενάσης και είναι ιδιαιτέρως χρήσιμα στη θεραπεία εξαρτώμενων από ουδετερόφιλα παθολογιών όπως ψωρίασης, ελκώδους κολίτιδας, μελανώματος, χρόνιας αποφρακτικής πνευμονικής ασθένειας (COPD), φλυκταινώδους πέμφιγος, ρευματοειδούς αρθρίτιδας, ιδιοπαθούς ίνωσης και στην πρόληψη και θεραπεία βλαβών που προκαλούνται από ισχαιμία και επαναιμάτωση.
Patent CY-1116363-T1 (CY)
Title: Μεθοδος για συζευξη βακτηριακου αντιγονου προς πρωτεϊνη φορεα
Inventor: BIEMANS RALPH LEON
IPC: A61P31/04
Filed: 2015-06-05
Abstract: Η παρούσα εφεύρεση αφορά σε μια μέθοδο σύζευξης ενός αντιγόνου που περιλαμβάνει τα στάδια a) ενεργοποίησης του αντιγόνου για να σχηματιστεί ενεργοποιημένο αντιγόνο· b) αντίδρασης του ενεργοποιημένου αντιγόνου και μιας πρωτεΐνης φορέα ή ενός συνδέτη για να σχηματιστεί μια ομάδα ιμίνης που συνδέει το ενεργοποιημένο αντιγόνο προς την πρωτεΐνη φορέα ή τον συνδέτη και c) αναγωγής της ομάδας ιμίνης χρησιμοποιώντας αναγωγικό παράγοντα που περιλαμβάνει χαρακτηριστική ομάδα τριακετοξυβοροϋδριδίου για να σχηματιστεί συζευγμένο αντιγόνο ή αντιγόνο-συνδέτης και προαιρετικώς d) αντίδρασης του αντιγόνου-συνδέτη με μια πρωτεΐνη φορέα για να σχηματιστεί συζευγμένο αντιγόνο· όπου προαιρετικώς το αντιγόνο προέρχεται από Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Salmonella Vi ή Staphylococcus epidermidis, προαιρετικώς περαιτέρω περιλαμβάνουσα στάδιο a') λυοφίλισης του ενεργοποιημένου παράγοντα και πρωτεΐνης φορέα που ακολουθείται από επανασύσταση σε DMSO ή DMF.
Patent CY-1120484-T1 (CY)
Title: Μειωση της γονοτοξικοτητας στο δοκιμαστικο σωληνα εκχυλισματων γυρης με αφαιρεση των φααβονοειδων
Inventor: MOINGEON PHILIPPE
IPC: C07K1/34
Filed: 2017-06-08
Abstract: Η εφεύρεση αναφέρεται σε εκχυλίσματα γύρης χόρτων που περιέχουν μειωμένη ποσότητα γλυκοζιτών φλαβονοειδών προκειμένου να ελαχιστοποιηθούν οι κίνδυνοι γονοτοξικότητας των εκχυλισμάτων της γύρης των χόρτων. Η εφεύρεση αναφέρεται επίσης σε μια μέθοδο παρασκευής εκχυλισμάτων γύρης χόρτων που περιέχουν μειωμένη ποσότητα γλυκοζιτών φλαβονοειδών, με υπερδιήθηση. Οι γλυκοζίτες φλαβονοειδών υπάρχουν φυσικά σε εκχυλίσματα γύρης χόρτων και έχουν ταυτοποιηθεί ως υπεύθυνοι για το σχηματισμό αγλυκονών φλαβονοειδών, oι οποίες είναι γονοτοξικές στο δοκιμαστικό σωλήνα, υπό την επίδραση ενζύμων που περιέχονται στα εκχυλίσματα της γύρης των χόρτων.
Patent CY-1122441-T1 (CY)
Title: Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
Inventor: BIGOT ANTONY
IPC: C07D413/06
Filed: 2019-11-06
Abstract: Η παρούσα εφεύρεση αναφέρεται σε ενώσεις κρυπτοφυκίνης του τύπου (I). Η εφεύρεση επίσης αναφέρεται σε φορτία κρυπτοφυκίνης, σε συζεύγματα κρυπτοφυκίνης, σε συνθέσεις τα περιέχουν και στη θεραπευτική χρήση τους, κυρίως ως αντικαρκινικοί παράγοντες. Η εφεύρεση επίσης αναφέρεται στη διαδικασία για την παρασκευή τέτοιων συζευγμάτων.
Patent GR-880300163-T1 (GR)
Title: Synthesis and application of high molecular weight polyanhydrides
Inventor: LANGER ROBERT S
IPC: C08G67/00
Filed: 1989-01-31
Abstract: High molecular weight polyanhydrides, defined as polyanhydrides having a molecular weight average greater than 20,000 or an intrinsic viscosity of greater than 0.3 dl/g in an organic solvent at room temperature, are formed by melt polycondensation of highly pure isolated prepolymers under optimized reaction conditions, particularly time and temperature with removal of the condensation product. Higher molecular weights are obtained by inclusion of a catalyst with the prepolymers in the melt polymerization. Catalysts used for transterification, ring opening polymerization and related polymerizations may be utilized. The high molecular weight polyanhydrides have improved physico-mechanical properties and are especially well suited for biomedical applications, particularly in controlled release devices for drug deliver.
Patent GR-900300020-T1 (GR)
Title: Pliers-type hand tool
Inventor: KERN PETER
IPC: B25G1/10
Filed: 1991-07-31
Abstract: In order to ergonomically optimize the hand side of combination pliers, whose gripping arms in each case form a mouth jaw on their ends and are in operative connection by means of a joint in such a way that in the case of different activities with the pliers the adaptation of the gripping arms to the anatomy and anthropometry of the human hand is retained, it is proposed that the gripping arms face one another elliptically in the plane thereof and that in the vicinity of the coupling surface to the hand the gripping arms have an elliptical cross-section.
Patent GR-930300061-T1 (GR)
Title: Process and apparatus for biological purification of waste waters polluted with non biodegradable or hardly biodegradable substances
Inventor: WAGNER FRIEDRICH DR-ING
IPC: C02F3/12
Filed: 1993-06-30
Abstract: According to the invention, the hardly biodegradable or non-biodegradable constituents are separated and concentrated to give a concentrate, the concentrate is preferably physically and/or chemically treated and the treated or untreated concentrate is subjected to a biological reaction or the concentrate is alternatively separated from the waste water to be purified. An apparatus for carrying out the process contains a membrane filtration device or nanofiltration device (19), to which the waste water having the hardly biodegradable or non-biodegradable constituents (16) to be concentrated is fed on the inlet side and in which the hardly biodegradable or non-biodegradable constituents are retained and from which the purified waste water (24) is discharged on the outlet side, and a filtration reservoir (15) connected to the membrane filtration device or nanofiltration device (19), which reservoir acts for concentration of the hardly biodegradable or non-biodegradable constituents of the waste water.
Patent HR-P20090610-T1 (HR)
Inventor: PETERS CHERYL L
IPC: C12Q1/48
Filed: 2009-11-13
Abstract: Izolirana molekula nukleinske kiseline, naznačena time, da je odabrana od: a)	molekule nukleinske kiseline koja sadrži nukleotidni odsječak SEQ ID NO: 1, 3 ili 5, ili njihov komplement; b)	molekule nukleinske kiseline koja sadrži nukleotidni odsječak koji ima najmanje 80% identitet odsječka nukleotidnom odsječku SEQ ID NO: 1, 3 ili 5 koji kodira toleranciju na glifosat EPSPS, ili njihov komplement; c)	nukleotidni odsječak tolerancije na glifosat DNK inserta plazmida pohranjenog pod pristupnim brojem NRRL B-30888 ili B-30949, ili njihov komplement; d)	molekule nukleinske kiseline koja kodira polipeptid koji sadrži aminokiselinski odsječak SEQ ID NO: 2, 4 ili 6; ie)	molekule nukleinske kiseline koja sadrži nukleotidni odsječak koji kodira polipeptid koji ima najmanje 80% identitet odsječka aminokiselinskom odsječku SEQ ID NO: 2, 4 ili 6, pri čemu rečeni polipeptid ima aktivnost tolerancije na glifosat. Patent sadrži još 13 patentnih zahtjeva.
Patent HR-P20110126-T1 (HR)
Title: Novel medicine pack
Inventor: KLATT ANDREAS
IPC: B65D75/34
Filed: 2011-02-21
Abstract: Medicine pack comprises blister units (1), each having a protective case (6), with a blister strip (4). The blister strip is fixedly connected to the protective case, which is capable of being unfolded or opened out. An outer package is provided for receiving the blister units. It is configured in a way that the pack content can be fixed in the inside of the outer package.
Patent SI-1525177-T1 (SI)
Title: Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
Inventor: NAJIB JAMILA
IPC: A61K31/192
Filed: 2003-07-08
Abstract: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.
Patent SI-1814534-T1 (SI)
Title: Derivatives of 5-aminolevulinic acid for the treatment of acne
Inventor: GODAL ASLAK
IPC: A61P17/00
Filed: 2005-11-04
Abstract: The invention provides use of a photosensitiser, which is a derivative (e.g., an ester) of 5-aminolevulinic acid (5-ALA) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of acne.
Patent SI-2066538-T1 (SI)
Title: Rollover wash unit and method for mounting a rollover wash unit
Inventor: WIMMER GEORG
IPC: B60S3/00
Filed: 2007-08-02
Abstract: A rollover wash unit for a vehicle wash system that allows an efficient and space-saving transport and a method for mounting a rollover wash unit that allows an efficient, simple and fast mounting of the rollover wash unit in situ.
Patent SI-2848610-T1 (SI)
Title: Inhibitors of kinase activity
Inventor: BURNS CHRISTOPHER JOHN
IPC: C07D241/00
Filed: 2007-11-15
Abstract: The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRbeta, PDGFRalpha or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.
Patent SI-2200621-T1 (SI)
Title: Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
Inventor: FREY II WILLIAM H
IPC: A61K35/30
Filed: 2008-09-04
Abstract: Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.
Patent TR-201812437-T1 (TR)
Title: Catalyst carrier and catalyst comprising same.
Inventor: JIANYU CHAI
IPC: B01J35/10
Filed: 2016-09-20
Abstract: The present application relates to a catalyst carrier for use in the synthesis of dialkyl oxalates by gas-phase catalysis of coupling on carbon monoxide comprising microscopic fine pores and one or more macroscopic large pores running through the catalyst carrier, wherein the ratio of the average pore diameter of each macroscopic large pore to the average diameter of the catalyst carrier is 0.2 or more. The present application also relates to a catalyst, comprising the catalyst carrier, an active component and an optional auxiliary, supported on the catalyst carrier. The catalyst according to the present invention not only catalyze effectively coupling on carbon monoxide in a gas phase to form dialkyl oxalate, but also improves heat dissipation, reduces pressure drop, reduces the amount applied of precious metal such as palladium, thereby reducing the use cost of the catalyst and production cost of dialkyl oxalate and then facilitating industrial mass production of dialkyl oxalate.
Patent DE-3486404-T2 (DE)
Inventor: ESSEX MYRON
IPC: G01N33/569
Filed: 1984-04-13
Granted: 1996-02-01
Abstract: A first glycoprotein having a molecular weight of approximately 61,000-68,000 daltons in the MJ, C5-MJ, C91 PL or HUT-102 cell lines, of which 46,000 to 48,000 is the unglycosylated moiety, is obtained from cells infected with human T cell leukemia virus. A second glycoprotein having a molecular weight of approximately 45,000-52,000 daltons is also obtained from such cells and is in large part identical to the NH2-terminal end of the first glycoprotein. The presence, in a biological specimen, of antibody to the antigenic determinant of either of these proteins is indicative of the presence of cells infected by human T cell leukemia virus. An assay for the antibody is a useful diagnostic procedure for determining such infection in biological specimens.